Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

Phase II study of AXS-05 for smoking cessation meets prespecified primary endpoint

April 16, 2019

Chronos Therapeutics presents orexin receptor antagonists

March 22, 2019

RGFP-966, an HDAC3 inhibitor, suppresses drug-seeking behavior in rats

Feb. 21, 2019

GPR39 agonist reduces alcohol intake in mouse model of alcohol use disorder

Feb. 19, 2019

Addex and Indivior intend to accelerate additional GABA-B PAM compounds for addiction

Feb. 14, 2019

Antidote Therapeutics to collaborate with NCI on development of ATI-1013

Feb. 8, 2019

Phase Ib data support expansion of indication for BioXcel's BXCL-501

Feb. 5, 2019

Phase II data for PF-04457845 as potential treatment of cannabis withdrawal and dependence

Jan. 15, 2019

Nanoscavenger versus neurotoxins

Jan. 7, 2019

ITI-333 shows promise for the treatment of pain and substance abuse-derived disorders

Dec. 24, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...